Making filtration devices easier to clean reduces fatigue and injury risk while improving reproducibility.

New flow imaging microscopy technology visualizes a broad range of subvisible particles hidden in therapeutic suspensions.  

Sandosh Padmanabhan and Andrew Morrow will discuss how pharmacogenomics methods improve precision medicine for cardiovascular disease treatment.

Scientists uncover the promise of mesenchymal stem cells (MSCs), also known as medicinal signaling cells, to modulate the immune system and regenerate tissue.

The sponsors of upwards of 1,000 clinical trials may be forced to publish data that have gone unpublished over a 10-year period.

The widely expected move comes months after the companies scrapped trials of another Alzheimer’s drug.

The drug promotes and sustains brain cell connectivity in mice, reversing the effects of chronic stress.

A prototype in-vein device would collect toxic medications before they reach healthy tissues.

This year’s winners are C. David Allis, Michael Grunstein, John Glen, and Joan Steitz.

As the CBD-based medication enters the market, the agency promises a crackdown on producers of cannabidiol products that make unproven claims.

Multidrug combinations lead to better results for cancer patients, but efficiently identifying them is proving difficult.

Researchers use several different strategies to deliver a one-two punch.

The company’s recent effort to find new treatments for Alzheimer’s ended in disappointment.

The Good Pharma Scorecard finds some big pharmaceutical companies are meeting legal standards for disclosing results—but many studies still go unreported.

If approved, patisiran will be the first RNAi therapeutic on the market. 

Three weeks after Hurricane Maria hit the island, pharmaceutical plants are not back up to speed.

A US government website for collecting reports of side effects associated with vaccines is broken. Why has no one noticed?

With its purchase of Actelion, Johnson & Johnson’s acquires experimental treatments for pulmonary arterial hypertension and several rare diseases.

The pharma giant’s purchase of the US firm includes the acquisition of investigative cancer drugs.